Pharmaceutical Business Review
Anonymous User | Login

Bafna Pharma To Launch Olmebaf In Sri Lanka

Published: 18-Nov-2009

For the treatment of hypertension

Bafna Pharmaceuticals has received approval from Sri Lankan authorities for the launch of Olmesartan Medoxomil, anti-hypertension drug. The drug will be launched as Olmebaf, and will initiate marketing in Sri Lanka next year.

The product will be sold directly by Bafna Pharma.

The company said: “The company is all set to market the brand by early 2010. Bafna Pharma is the only Indian company to market the branded product 'Olmebaf' in the Sri Lanka market for the treatment of hypertension.

“The Sri Lankan market for these product segments is expected to grow at a rate of up to 10 per cent annually for at least the next five years.''

Drug Controller General of India (DCGI) has earlier approved Olmesartan Medoxomil in combination with Hydrochlorothiazide as anti-hypertensive drug.

Mahaveer Chand Bafna, chairman and MD of Bafna, said: “We are delighted to now have our direct presence in Sri Lanka market. We have invested in developing infrastructure and getting the team in place for the long term implementation of our strategy for the market.''

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ADAPT Localization

The Translation and Localization Specialists ...

Anoto

Providing Unique Technology for Digital Pen and Paper ...

Aptuit

Drug Discovery and Development ...

Bachem

Process Development and Manufacturing of Peptides and Complex Organic Molecules as APIs ...

BaseCon

IT Pharma Solutions ...

Bioceros

Pre-Clinical Development of Monoclonal Antibodies and Generation of GMP-Ready Proteins ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

GRACO's New FDA Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New Hydra-Clean

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

GRACO's New 1590 & 3150 Pumps

The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

Customer Testimonial – Astra Zeneca

From the control room to the downstream processing area and with an eye on utilities servi ...

Hygienic Processing

From the control room to the downstream processing area and with an eye on utilities servi ...

Related Companies

No items to display

Suppliers Product News

Organisations Throwing Mobile Technology at Problems With Little Consideration of Actual User and Business Needs, Quocirca

Survey reveals detrimental impact on organisational effectiveness and IT expenditure in healthcare and finance across the UK, France, Germany and the US.

Digital Pen and Paper Technology Helps Accelerate Clinical Trials

Digital pen and paper technology captures handwritten clinical data electronically, quickly and securely to save time and cost in drug discovery process.

Aptuit Outlines 2010 Business Priorities at 28th Annual J.P. Morgan Healthcare Conference

Aptuit, Inc., a contract development and manufacturing company, today will provide an update on 2010 business priorities and discuss its integrated service offerings at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

Aptuit Publishes Study which Demonstrates the Value of Early Insights into the Characterisation of Drug Compounds

New research on the solid-state characterisation of finasteride clearly outlines a systematic approach to characterising and monitoring active pharmaceutical ingredients

Aptuit Launches Program to Accelerate Early Stage Drug Development

Aptuit INDiGO™ accelerates drug development from pre-clinical candidate selection to regulatory filing on a fixed timeline and price

mondoBIOTECH and Bachem Agree Long-Term Cooperation on the Development of Peptides to Fight Rare Diseases

mondoBIOTECH and Bachem on 24 September announced the conclusion of a longterm cooperation.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address